trending Market Intelligence /marketintelligence/en/news-insights/trending/pmityqscphcqjikxo-fptw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Regeneron, Alnylam team up to find genetic therapies for liver disease

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Regeneron, Alnylam team up to find genetic therapies for liver disease

New York-based Regeneron Pharmaceuticals Inc. will collaborate with Alnylam Pharmaceuticals Inc. to develop genetic therapies for the chronic liver disease called nonalcoholic steatohepatitis and potentially other related diseases.

Nonalcoholic steatohepatitis is a condition in which fat builds up in the liver and causes inflammation and damage to liver cells.

The companies will use Massachusetts-based Alnylam's RNA interference therapeutics platform, a system that can target and silence a selected gene, and Regeneron's research work on a gene known as HSD17B13.

A recent study by Regeneron showed that the loss of function in HSD17B13 results in a reduced risk of chronic liver diseases.

The companies intend to enter into a separate, 50-50 collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts.

This is the second collaboration between Regeneron and Alnylam involving genetic exploration in 2018.